Medtronic reported a 13% decrease in Q1 revenue to $6.507 billion, with a GAAP diluted EPS of $0.36 and a non-GAAP diluted EPS of $0.62. The results were impacted by the COVID-19 pandemic, but the company saw a faster than expected recovery with improving procedure volumes.
Q1 revenue decreased by 13% as reported, and approximately 17% organic.
GAAP diluted EPS was $0.36, while non-GAAP diluted EPS was $0.62.
Procedure volumes began to recover around the world.
The company is leveraging its pipeline of innovative products to drive share gains.
Given the uncertainty on near-term financial results caused by the COVID-19 pandemic, the company is not providing formal annual or quarterly financial guidance at this time.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance